Adult xanthogranulomatous disease of the orbit: case report of spontaneous regression and review of treatment modalities

References

• Bijlsma WR, van Den Bosch WA, van Daele PL, Paridaens D. Azathioprine and prednisone combination treatment for adult periocular and orbital xanthogranulomatous disease. Acta Ophthalmol. 2011;89:e278–82. doi:10.1111/j.1755-3768.2009.01726.x.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Whitehead K, Quagliotto G, et al. Adult orbital and adnexal xanthogranulomatous disease. Asia Pac J Ophthalmol (Phila). 2017;6:435–443. doi:10.22608/APO.2017246.
   PubMed Web of Science ®Google Scholar
• Guo J, Wang J. Adult orbital xanthogranulomatous disease: review of the literature. Arch Pathol Lab Med. 2009;133:1994–1997. doi:10.1043/1543-2165-133.12.1994.
   PubMed Web of Science ®Google Scholar
• Sivak-Callcott JA, Rootman J, Rasmussen SL, et al. Adult xanthogranulomatous disease of the orbit and ocular adnexa: new immunohistochemical findings and clinical review. Br J Ophthalmol. 2006;90:602–608. doi:10.1136/bjo.2005.085894.
   PubMed Web of Science ®Google Scholar
• Jakobiec FA, Mills MD, Hidayat AA, et al. Periocular xanthogranulomas associated with severe adult-onset asthma. Trans Am Ophthalmol Soc. 1993;91:99–125. discussion 25-9.
   PubMedGoogle Scholar
• Shimizu F, Taneda H, Sato H, et al. A case of orbital xanthogranuloma treated by surgical excision. Case Rep Dermatol. 2010;2:110–115. doi:10.1159/000316807.
   PubMedGoogle Scholar
• Ebrahimi KB, Miller NR, Sassani JW, et al. Failure of radiation therapy in orbital xanthogranuloma. Ophthalmic Plast Reconstr Surg. 2010;26:259–264. doi:10.1097/IOP.0b013e3181bd4356.
   PubMed Web of Science ®Google Scholar
• Ugurlu S, Bartley GB, Gibson LE. Necrobiotic xanthogranuloma: long-term outcome of ocular and systemic involvement. Am J Ophthalmol. 2000;129:651–657.
   PubMed Web of Science ®Google Scholar
• Hayden A, Wilson DJ, Rosenbaum JT. Management of orbital xanthogranuloma with methotrexate. Br J Ophthalmol. 2007;91:434–436. doi:10.1136/bjo.2006.109587.
   PubMed Web of Science ®Google Scholar
• Meyer S, Szeimies RM, Landthaler M, Hohenleutner S. Cyclophosphamide-dexamethasone pulsed therapy for treatment of recalcitrant necrobiotic xanthogranuloma with paraproteinemia and ocular involvement. Br J Dermatol. 2005;153:443–445. doi:10.1111/j.1365-2133.2005.06737.x.
   PubMed Web of Science ®Google Scholar
• Kiratli H, Kilic M, Tarlan B, Soylemezoglu F. Adult orbital xanthogranulomas: clinical features and management. Eur J Ophthalmol. 2015;25:288–292. doi:10.5301/ejo.5000555.
   PubMed Web of Science ®Google Scholar
• Vieira V, Del Pozo J, Martinez W, et al. Necrobiotic xanthogranuloma associated with lymphoplasmacytic lymphoma. Palliative treatment with carbon dioxide laser. Eur J Dermatol. 2005;15:182–185.
   PubMed Web of Science ®Google Scholar
• Wee SA, Shupack JL. Necrobiotic xanthogranuloma. Dermatol Online J. 2005;11:24.
   PubMedGoogle Scholar
• Char DH, LeBoit PE, Ljung BM, Wara W. Radiation therapy for ocular necrobiotic xanthogranuloma. Arch Ophthalmol. 1987;105:174–175.
   PubMedGoogle Scholar
• Lau WW, Chan E, Chan CW. Orbital involvement in erdheim-chester disease. Hong Kong Med J. 2007;13:238–240.
   PubMedGoogle Scholar
• Finelli LG, Ratz JL. Plasmapheresis, a treatment modality for necrobiotic xanthogranuloma. J Am Acad Dermatol. 1987;17:351–354.
   PubMed Web of Science ®Google Scholar
• Hauser C, Schifferli J, Saurat JH. Complement consumption in a patient with necrobiotic xanthogranuloma and paraproteinemia. J Am Acad Dermatol. 1991;24:908–911.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Hofbauer G, Burg G. Necrobiotic xanthogranuloma with monoclonal gammopathy of the igg lambda type. Dermatology. 1999;198:434–435.
   PubMed Web of Science ®Google Scholar
• Finan MC, Winkelmann RK. Necrobiotic xanthogranuloma with paraproteinemia. A review of 22 cases. Medicine (Baltimore). 1986;65:376–388.
   PubMed Web of Science ®Google Scholar
• Flann S, Wain EM, Halpern S, et al. Necrobiotic xanthogranuloma with paraproteinaemia. Clin Exp Dermatol. 2006;31:248–251. doi:10.1111/j.1365-2230.2005.02042.x.
   PubMed Web of Science ®Google Scholar
• Elner VM, Mintz R, Demirci H, Hassan AS. Local corticosteroid treatment of eyelid and orbital xanthogranuloma. Ophthalmic Plast Reconstr Surg. 2006;22:36–40.
   PubMed Web of Science ®Google Scholar
• Silapunt S, Chon SY. Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide. J Drugs Dermatol. 2010;9:273–276.
   PubMed Web of Science ®Google Scholar
• Hammond MD, Niemi EW, Ward TP, Eiseman AS. Adult orbital xanthogranuloma with associated adult-onset asthma. Ophthalmic Plast Reconstr Surg. 2004;20:329–332.
   PubMed Web of Science ®Google Scholar
• Chave TA, Chowdhury MM, Holt PJ. Recalcitrant necrobiotic xanthogranuloma responding to pulsed high-dose oral dexamethasone plus maintenance therapy with oral prednisolone. Br J Dermatol. 2001;144:158–161.
   PubMed Web of Science ®Google Scholar
• Plotnick H, Taniguchi Y, Hashimoto K, et al. Periorbital necrobiotic xanthogranuloma and stage i multiple myeloma. Ultrastructure and response to pulsed dexamethasone documented by magnetic resonance imaging. J Am Acad Dermatol. 1991;25:373–377.
   PubMed Web of Science ®Google Scholar
• Cornblath WT, Dotan SA, Trobe JD, Headington JT. Varied clinical spectrum of necrobiotic xanthogranuloma. Ophthalmology. 1992;99:103–107.
   PubMed Web of Science ®Google Scholar
• Kerstetter J, Wang J. Adult orbital xanthogranulomatous disease: a review with emphasis on etiology, systemic associations, diagnostic tools, and treatment. Dermatol Clin. 2015;33:457–463. doi:10.1016/j.det.2015.03.010.
   PubMed Web of Science ®Google Scholar
• Satchi K, McNab AA, Godfrey T, Prince HM. Adult orbital xanthogranuloma successfully treated with rituximab. Ophthalmology. 2014;121(1664–5):e1–3. doi:10.1016/j.ophtha.2014.02.024.
   PubMedGoogle Scholar
• Papagoras C, Kitsos G, Voulgari PV, et al. Periocular xanthogranuloma: a forgotten entity? Clin Ophthalmol. 2010;4:105–110.
   PubMedGoogle Scholar
• Olson RM, Harrison AR, Maltry A, Mokhtarzadeh A. Periorbital necrobiotic xanthogranuloma successfully treated with intravenous immunoglobulin. Case Rep Ophthalmol. 2018;9:70–75. doi:10.1159/000485913.
   PubMed Web of Science ®Google Scholar
• Lukacs J, Goetze S, Elsner P. Periocular necrobiotic xanthogranuloma successfully treated with intravenous immunoglobulin. Acta Derm Venereol. 2017;97:754–755. doi:10.2340/00015555-2626.
   PubMed Web of Science ®Google Scholar
• Hallermann C, Tittelbach J, Norgauer J, Ziemer M. Successful treatment of necrobiotic xanthogranuloma with intravenous immunoglobulin. Arch Dermatol. 2010;146:957–960. doi:10.1001/archdermatol.2010.236.
   PubMedGoogle Scholar
• Georgiou S, Monastirli A, Kapranos N, et al. Interferon alpha-2a monotherapy for necrobiotic xanthogranuloma. Acta Derm Venereol. 1999;79:484–485. doi:10.1080/00015559975001003.
   PubMed Web of Science ®Google Scholar
• Venencie PY, Le Bras P, Toan ND, et al. Recombinant interferon alfa-2b treatment of necrobiotic xanthogranuloma with paraproteinemia. J Am Acad Dermatol. 1995;32:666–667.
   PubMed Web of Science ®Google Scholar
• Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory erdheim-chester disease and langerhans cell histiocytosis harboring the braf v600e mutation. Blood. 2013;121:1495–1500. doi:10.1182/blood-2012-07-446286.
   PubMed Web of Science ®Google Scholar
• Gupta A, Yeganeh A, Rootman D, Vemurafenib GR. (braf inhibitor) therapy for orbital erdheim-chester disease. Ophthalmic Plast Reconstr Surg. 2017;33:e138–e39. doi:10.1097/IOP.0000000000000866.
   PubMed Web of Science ®Google Scholar
• Myra C, Sloper L, Tighe PJ, et al. Treatment of erdheim-chester disease with cladribine: a rational approach. Br J Ophthalmol. 2004;88:844–847.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Vogelzang NJ, O’Brien SM, et al. A phase i study of intermittent infusion cladribine in patients with solid tumors. Cancer. 1994;74:168–173.
   PubMed Web of Science ®Google Scholar
• Sheidow TG, Nicolle DA, Heathcote JG. Erdheim-chester disease: two cases of orbital involvement. Eye (Lond). 2000;14(Pt 4):606–612. doi:10.1038/eye.2000.151.
   PubMedGoogle Scholar
• Luck J, Layton A, Noble BA. Necrobiotic xanthogranuloma with orbital involvement. J R Soc Med. 1992;85:357–358.
   PubMed Web of Science ®Google Scholar
• Machado S, Alves R, Lima M, et al. Cutaneous necrobiotic xanthogranuloma (nxg)–successfully treated with low dose chlorambucil. Eur J Dermatol. 2001;11:458–462.
   PubMed Web of Science ®Google Scholar
• Mahendran P, Wee J, Chong H, Natkunarajah J. Necrobiotic xanthogranuloma treated with lenalidomide. Clin Exp Dermatol. 2018;43:345–347. doi:10.1111/ced.13293.
   PubMed Web of Science ®Google Scholar
• Criado PR, Vasconcellos C, Pegas JR, et al. Necrobiotic xanthogranuloma with lambda paraproteinemia: case report of successful treatment with melphalan and prednisone. J Dermatolog Treat. 2002;13:87–89. doi:10.1080/095466302317584458.
   PubMed Web of Science ®Google Scholar
• Rayner SA, Duncombe AS, Keefe M, et al. Necrobiotic xanthogranuloma occurring in an eyelid scar. Orbit. 2008;27:191–194. doi:10.1080/01676830701804057.
   PubMedGoogle Scholar
• Saeki H, Tomita M, Kai H, et al. Necrobiotic xanthogranuloma with paraproteinemia successfully treated with melphalan, prednisolone and skin graft. J Dermatol. 2007;34:795–797. doi:10.1111/j.1346-8138.2007.00387.x.
   PubMed Web of Science ®Google Scholar
• Saad N, Skowron F, Dalle S, et al. Multiple adult xanthogranuloma: case report and literature review. Dermatology. 2006;212:73–76. doi:10.1159/000089027.
   PubMed Web of Science ®Google Scholar